Sourcing Japanese Pharmaceuticals as Unlicensed Medicines (Specials) in the UK

What Are Unlicensed Medicines (Specials) in the UK?

In the United Kingdom, certain patients have clinical needs that cannot be met by medicines holding a UK Marketing Authorisation. The Human Medicines Regulations 2012 (Regulation 167) permits the importation of unlicensed medicines—commonly referred to as “Specials” or “imported unlicensed medicines”—when no suitable licensed alternative is available.

This legal pathway is well-established and widely used across the NHS and private healthcare sector. Hundreds of Special order products are prescribed regularly across England, covering everything from reformulated dosage forms to medicines licensed in other countries but not in the UK.

Japan is a particularly relevant source country for this purpose. Japan’s pharmaceutical market is the third-largest in the world, and its domestic approval pipeline includes a wide range of compounds that are either unavailable, unlicensed, or classified as orphan drugs in the UK.

Why Japan Is a Relevant Source for UK Specials

1. Broad Domestic Approval Scope

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved a range of compounds that have not received UK Marketing Authorisation. This includes treatments for rare neurological conditions, specific oncology indications, and metabolic disorders.

2. GMP and GDP Compliance

Japanese pharmaceutical manufacturers operate under internationally recognised Good Manufacturing Practice (GMP) standards consistent with PIC/S guidelines. This is a prerequisite for MHRA-compliant import of unlicensed medicines.

3. Country-Specific Orphan Drug Designations

Regulatory designations differ by jurisdiction. A medicine classified as a standard approved product in Japan may carry orphan drug status in the UK or EU—and vice versa. A well-documented example is chenodeoxycholic acid: available as a standard approved medicine in Japan, but designated as an orphan drug in the EU and UK for cerebrotendinous xanthomatosis (CTX). Japanese-manufactured stock therefore represents a legitimate, GMP-compliant source for UK Specials procurement.

Regulatory Requirements for Importing from Japan

• Importer’s licence: The UK importer must hold a Wholesale Dealer’s Authorisation (WDA(H)) with importation endorsement, or a Specials Manufacturing Authorisation (MS) with import scope.
• Notification of intent: A formal Notification of Intent must be submitted to the MHRA at least 28 days before the first importation of each product.
• Clinical justification: A registered UK healthcare professional must confirm the clinical need.
• GDP compliance: The entire supply chain must comply with Good Distribution Practice guidelines, including temperature-controlled transport where applicable.
• Labelling: Imported Specials must indicate unlicensed status; overlabelling in English is typically required.
• Quality assessment: Each imported Special must be subject to local quality assessment per NHS SPS guidance.

Documents Available from Japanese Exporters

Therapeutic Categories of Interest for UK Specials

• Rare metabolic disorders: Enzyme therapies for lysosomal storage disorders and urea cycle defects.
• Neurology and movement disorders: Agents for spinocerebellar ataxia, ALS, and myasthenia gravis.
• Oncology (supportive and adjunct): Chemotherapy adjuncts used in Japanese oncology practice.
• Ophthalmology: Eye drops and surgical adjuncts with strong representation in Japan’s approved product base.
• Endocrinology: Growth hormone preparations, gonadotropins, and thyroid-related compounds.

How TASAKI PHARMA Supports UK Specials Procurement

TASAKI PHARMA is a Taiwan-based pharmaceutical trading company with GDP and PIC/S GMP-compliant operations, specialising in the export of Japanese-origin pharmaceutical products to healthcare institutions worldwide.

• Access to Japan-approved ethical medicines via J-Lex (db.tasakipharma.com)
• Certificate of Origin (CoO) and Patient Information Leaflet (PIL) upon request
• GDP-compliant logistics including temperature-controlled shipping and data loggers
• Ex Works pricing in USD, EUR, or JPY
• Proforma Invoice and standard export documentation

Enquiry Process

1. Search J-Lex for the product of interest
2. Submit an enquiry with your pharmaceutical licence details
3. Receive a quotation (Ex Works)
4. Place order based on quotation
5. Receive Proforma Invoice; payment processed prior to dispatch
6. Shipment arranged with full GDP documentation

Frequently Asked Questions

Is it legal to import Japanese medicines into the UK as Specials?

Yes. Under Regulation 167 of the Human Medicines Regulations 2012, unlicensed medicines may be imported when no licensed alternative is available, subject to MHRA notification and clinical justification requirements.

Are Japanese pharmaceuticals GMP compliant?

Japan is a PIC/S member country. Japanese manufacturers operate under GMP standards mutually recognised by MHRA—a standard requirement for MHRA-compliant Specials importation.

Can you provide a Certificate of Origin?

Yes. CoO, PIL, and other standard export documentation are available upon request for products sourced through TASAKI PHARMA.